verapamil has been researched along with perhexiline in 43 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 31 (72.09) | 18.7374 |
| 1990's | 2 (4.65) | 18.2507 |
| 2000's | 6 (13.95) | 29.6817 |
| 2010's | 4 (9.30) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Cavalli, A; De Ponti, F; Poluzzi, E; Recanatini, M | 1 |
| Keserü, GM | 1 |
| Li, J; Rajamani, R; Reynolds, CH; Tounge, BA | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Jia, L; Sun, H | 1 |
| Caron, G; Ermondi, G; Visentin, S | 1 |
| Sen, S; Sinha, N | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Sowton, E | 1 |
| Breithaupt, H; Walter, P | 1 |
| de Brito, FS; Pereira, MH | 1 |
| De'Thomatis, M; Falciola, N; Gallesio, R | 1 |
| Short, D | 1 |
| Candau, LA; de Patta, M; Padilha, JC; Scherr, C; Tasca, R; Weiskopf, JS | 1 |
| Attal, M; Bordier, C; Chatelain, P; Chiron, M; Jaffrézou, JP; Laurent, G; Levade, T; Thurneyssen, O | 1 |
| Carrière, D; Chiron, M; Grandjean, H; Jaffrézou, JP; Kuhlein, E; Laurent, G; Levade, T; Thurneyssen, O | 1 |
| Atkins, C; Bax, M; Psychoyos, S | 1 |
| Martre, H; Singlas, E; Taburet, AM | 1 |
| Briscoe, MG; Smith, HJ | 1 |
| Barry, WH; Horowitz, JD; Smith, TW | 1 |
| Opie, LH | 1 |
| Fossati, C; Guistiniani, S | 1 |
| Lewis, JG | 1 |
| Donath, M; Ebner, F; Rämsch, KD | 1 |
| Feely, J; Maclean, D | 1 |
| Deierkauf, M; Elferink, JG | 1 |
| Becker, HJ; Dowinsky, S; Hopf, R; Kaltenbach, M; Kober, G | 1 |
| Oguro, K; Ono, H | 1 |
| Forman, R; Kirk, ES | 1 |
| Hashimoto, K; Ohara, N; Ono, H | 1 |
| Dipalma, JR | 1 |
| Hochrein, H; Lehmann, HU | 1 |
| Antman, EM; Braunwald, E; Muller, JE; Stone, PH | 1 |
| Hayakawa, H; Kimura, E; Kishida, H; Kusama, Y; Otsu, F; Takayama, M | 1 |
| Kimura, M; Ono, H | 1 |
| Bergey, JL; McCallum, JD; Nocella, K | 1 |
| Nayler, WG | 1 |
| Flaim, SF; Zelis, R | 1 |
| Hashimoto, K; O'Hara, N; Ono, H | 1 |
| Aziza, JP; Blanchard, D; Guermonprez, JL; Lancelin, B; Maurice, P | 1 |
10 review(s) available for verapamil and perhexiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
[Treatment of angina pectoris (III)].
Topics: Angina Pectoris; Angina Pectoris, Variant; Coronary Artery Bypass; Humans; Nifedipine; Perhexiline; Prenylamine; Vasodilator Agents; Verapamil | 1979 |
[Medical therapy of chronic coronary insufficiency].
Topics: Amiodarone; Angina Pectoris; Chronic Disease; Coronary Disease; Digitalis Glycosides; Humans; Lidoflazine; Oxyfedrine; Perhexiline; Practolol; Prenylamine; Verapamil | 1978 |
[Clinical pharmacology of calcium inhibitors].
Topics: Age Factors; Animals; Bepridil; Biological Availability; Biotransformation; Calcium Channel Blockers; Diltiazem; Dogs; Half-Life; Humans; Intestinal Absorption; Kidney Failure, Chronic; Kinetics; Liver Diseases; Metabolic Clearance Rate; Nifedipine; Perhexiline; Protein Binding; Pyrrolidines; Rats; Tissue Distribution; Verapamil | 1985 |
[Side-effects of calcium antagonists].
Topics: Calcium Channel Blockers; Cardiovascular Diseases; Drug Hypersensitivity; Drug Interactions; Fendiline; Gastrointestinal Diseases; Humans; Lidoflazine; Nervous System Diseases; Nifedipine; Perhexiline; Prenylamine; Verapamil | 1984 |
Adverse reactions to calcium antagonists.
Topics: Calcium Channel Blockers; Diltiazem; Drug Interactions; Humans; Kinetics; Lidoflazine; Nifedipine; Perhexiline; Prenylamine; Risk; Verapamil | 1983 |
Clinical differentiation of nifedipine and other calcium antagonists.
Topics: Biological Availability; Calcium Channel Blockers; Diltiazem; Drug Tolerance; Heart Diseases; Hemodynamics; Humans; Kinetics; Nifedipine; Perhexiline; Verapamil | 1984 |
[Treatment of angina pectoris with calcium antagonists].
Topics: Angina Pectoris; Calcium Channel Blockers; Coronary Disease; Diltiazem; Drug Therapy, Combination; Exercise Test; Fendiline; Humans; Nicardipine; Nifedipine; Perhexiline; Prenylamine; Propafenone; Propiophenones; Verapamil | 1982 |
[Indications for use of calcium antagonists].
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Calcium; Cardiotonic Agents; Coronary Disease; Female; Fendiline; Humans; Hyperinsulinism; Hypertension; Nifedipine; Obstetric Labor, Premature; Paraganglioma; Perhexiline; Pregnancy; Prenylamine; Vasodilator Agents; Verapamil | 1980 |
Calcium channel blocking agents in the treatment of cardiovascular disorders. Part II: Hemodynamic effects and clinical applications.
Topics: Benzazepines; Calcium Channel Blockers; Cardiovascular Diseases; Coronary Circulation; Diltiazem; Hemodynamics; Humans; Myocardial Contraction; Nifedipine; Nitrogen; Perhexiline; Piperidines; Pyridines; Regional Blood Flow; Vasodilation; Verapamil | 1980 |
1 trial(s) available for verapamil and perhexiline
| Article | Year |
|---|---|
[Verapamil in the treatment of angina pectoris. Double-blind study with clinical and ergometric evaluation].
Topics: Adult; Aged; Angina Pectoris; Blood Pressure; Clinical Trials as Topic; Double-Blind Method; Electrocardiography; Exercise Test; Female; Heart Rate; Humans; Male; Middle Aged; Perhexiline; Piperidines; Placebos; Verapamil | 1979 |
32 other study(ies) available for verapamil and perhexiline
| Article | Year |
|---|---|
Toward a pharmacophore for drugs inducing the long QT syndrome: insights from a CoMFA study of HERG K(+) channel blockers.
Topics: Anti-Arrhythmia Agents; Cation Transport Proteins; Cluster Analysis; Databases, Factual; Ether-A-Go-Go Potassium Channels; Long QT Syndrome; Models, Molecular; Molecular Conformation; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2002 |
Prediction of hERG potassium channel affinity by traditional and hologram qSAR methods.
Topics: Cation Transport Proteins; Databases, Factual; Discriminant Analysis; Ether-A-Go-Go Potassium Channels; Holography; Linear Models; Potassium Channel Blockers; Potassium Channels; Potassium Channels, Voltage-Gated; Quantitative Structure-Activity Relationship | 2003 |
A two-state homology model of the hERG K+ channel: application to ligand binding.
Topics: ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Ligands; Models, Biological; Models, Molecular; Potassium Channels, Voltage-Gated; Protein Binding; Protein Conformation | 2005 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Support vector machines classification of hERG liabilities based on atom types.
Topics: Animals; Arrhythmias, Cardiac; CHO Cells; Computer Simulation; Cricetinae; Cricetulus; Discriminant Analysis; ERG1 Potassium Channel; Ether-A-Go-Go Potassium Channels; Humans; Models, Chemical; Patch-Clamp Techniques; Potassium Channel Blockers; Potassium Channels, Voltage-Gated; Predictive Value of Tests; ROC Curve | 2008 |
GRIND-based 3D-QSAR and CoMFA to investigate topics dominated by hydrophobic interactions: the case of hERG K+ channel blockers.
Topics: Ether-A-Go-Go Potassium Channels; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Potassium Channel Blockers; Quantitative Structure-Activity Relationship | 2009 |
Predicting hERG activities of compounds from their 3D structures: development and evaluation of a global descriptors based QSAR model.
Topics: Computer Simulation; Ether-A-Go-Go Potassium Channels; Humans; Molecular Structure; Organic Chemicals; Quantitative Structure-Activity Relationship | 2011 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
The treatment of angina pectoris.
Topics: Adrenergic beta-Antagonists; Angina Pectoris; Coronary Angiography; Humans; Isosorbide Dinitrate; Middle Aged; Nifedipine; Nitroglycerin; Perhexiline; Physical Exertion; Prenylamine; Verapamil | 1979 |
The management of the patient with angina.
Topics: Angina Pectoris; Anticoagulants; Clofibrate; Coronary Artery Bypass; Diazepam; Digoxin; Humans; Isosorbide Dinitrate; Nitroglycerin; Oxprenolol; Perhexiline; Prenylamine; Propranolol; Verapamil | 1977 |
Drug treatment of chronic stable angina pectoris.
Topics: Angina Pectoris; Chronic Disease; Humans; Nifedipine; Nitrites; Perhexiline; Verapamil | 1978 |
[Comparative study of the medium term use of verapamil and perhexiline in the treatment of chronic coronary insufficiency. Clinical and cycloergometric evaluation].
Topics: Adult; Aged; Chronic Disease; Coronary Disease; Electrocardiography; Exercise Test; Female; Humans; Male; Middle Aged; Perhexiline; Piperidines; Placebos; Verapamil | 1978 |
In vitro and in vivo enhancement of ricin-A chain immunotoxin activity by novel indolizine calcium channel blockers: delayed intracellular degradation linked to lipidosis induction.
Topics: Ammonium Chloride; Antibodies, Monoclonal; Dose-Response Relationship, Drug; Drug Synergism; Humans; Immunotoxins; Indolizines; Lipidoses; Lymphoma, T-Cell; Monensin; Perhexiline; Phenethylamines; Ricin; Tumor Cells, Cultured; Verapamil | 1992 |
Enhancement of ricin A chain immunotoxin activity by perhexiline on established and fresh leukemic cells.
Topics: Ammonium Chloride; Antibodies, Monoclonal; Cell Line; Humans; Immunotoxins; Kinetics; Leukemia, Lymphocytic, Chronic, B-Cell; Monensin; Neoplasm Proteins; Perhexiline; Ricin; Tumor Cells, Cultured; Verapamil | 1990 |
Differences in Ca2+ entry blockers revealed by effects on adenosine- and adrenergic- receptors and cyclic AMP levels of [2-3H]adenine-prelabeled vesicles prepared from guinea pig brain.
Topics: Adenine; Adenosine; Animals; Arrhythmias, Cardiac; Brain Chemistry; Calcium Channel Blockers; Cell Membrane; Cyclic AMP; Epinephrine; Guinea Pigs; In Vitro Techniques; Nifedipine; Perhexiline; Prenylamine; Receptors, Adrenergic; Receptors, Cell Surface; Receptors, Purinergic; Stereoisomerism; Tritium; Verapamil | 1986 |
The relative sensitization by acidosis of five calcium blockers in cat papillary muscles.
Topics: Acidosis; Animals; Calcium Channel Blockers; Cats; Diltiazem; In Vitro Techniques; Lidoflazine; Myocardial Contraction; Nifedipine; Papillary Muscles; Perhexiline; Verapamil | 1985 |
Comparison of negative inotropic potency, reversibility, and effects on calcium influx of six calcium channel antagonists in cultured myocardial cells.
Topics: Animals; Calcium; Calcium Channel Blockers; Cells, Cultured; Chick Embryo; Gallopamil; Half-Life; Lidoflazine; Myocardial Contraction; Myocardium; Nifedipine; Perhexiline; Time Factors; Verapamil | 1985 |
Drugs and the heart. III. Calcium antagonists.
Topics: Angina Pectoris; Aniline Compounds; Arrhythmias, Cardiac; Calcium; Cardiomegaly; Diuretics; Heart Diseases; Heart Failure; Humans; Hypertension; Indapamide; Nifedipine; Perhexiline; Piperidines; Pyridines; Verapamil | 1980 |
Calcium antagonists, nitrates, and new antianginal drugs.
Topics: Angina Pectoris; Calcium Channel Blockers; Humans; Hypertension; Isosorbide Dinitrate; Lidoflazine; Nifedipine; Nitrates; Nitroglycerin; Perhexiline; Prenylamine; Tachycardia; Verapamil | 1983 |
The effect of verapamil and other calcium antagonists on chemotaxis of polymorphonuclear leukocytes.
Topics: Animals; Calcium; Calcium Channel Blockers; Cell Survival; Chemotaxis, Leukocyte; Diltiazem; Gallopamil; Magnesium; Neutrophils; Perhexiline; Prenylamine; Rabbits; Verapamil | 1984 |
Effects of perhexiline on contractile response of rabbit aorta to norepinephrine and potassium.
Topics: Animals; Aorta, Thoracic; Drug Interactions; In Vitro Techniques; Muscle Contraction; Muscle, Smooth, Vascular; Nitroglycerin; Norepinephrine; Perhexiline; Piperidines; Potassium; Rabbits; Verapamil | 1980 |
Comparative effects of vasodilator drugs on large and small coronary resistance vessels in the dog.
Topics: Animals; Coronary Vessels; Dogs; Nifedipine; Nitroglycerin; Nitroprusside; Perhexiline; Vascular Resistance; Vasodilator Agents; Verapamil | 1980 |
Effect of an antianginal drug, perhexiline, on myocardial oxygen consumption in anesthetized open-chest dogs compared with verapamil and glyceryl trinitrate.
Topics: Animals; Blood Pressure; Cardiac Surgical Procedures; Coronary Circulation; Dogs; Dose-Response Relationship, Drug; Heart Rate; Heart Ventricles; Myocardium; Nitroglycerin; Oxygen Consumption; Perhexiline; Piperidines; Verapamil | 1982 |
Calcium channel blockers.
Topics: Angina Pectoris; Angina Pectoris, Variant; Arrhythmias, Cardiac; Calcium Channel Blockers; Diltiazem; Half-Life; Heart Diseases; Humans; Hypertension; Kinetics; Myocardial Infarction; Nifedipine; Perhexiline; Vasodilator Agents; Verapamil | 1983 |
Effects of calcium antagonists, especially nifedipine, on variant angina, resting angina, and unstable angina.
Topics: Aged; Angina Pectoris; Angina Pectoris, Variant; Calcium Channel Blockers; Coronary Vasospasm; Diltiazem; Female; Humans; Male; Middle Aged; Nifedipine; Perhexiline; Prenylamine; Pyridines; Rest; Verapamil | 1982 |
Effect of Ca2+-antagonistic vasodilators, diltiazem, nifedipine, perhexiline and verapamil, on platelet aggregation in vitro.
Topics: Adenosine Diphosphate; Adolescent; Adult; Calcium; Collagen; Diltiazem; Epinephrine; Humans; In Vitro Techniques; Male; Nifedipine; Perhexiline; Platelet Aggregation; Vasodilator Agents; Verapamil | 1981 |
Antiarrhythmic evaluation of verapamil, nifedipine, perhexiline and skf 525-A in four canine models of cardiac arrhythmias.
Topics: Animals; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Blood Pressure; Calcium; Dogs; Female; Heart Rate; Lidocaine; Male; Myocardial Contraction; Nifedipine; Perhexiline; Piperidines; Proadifen; Pyridines; Verapamil | 1981 |
Calcium antagonists.
Topics: Angina Pectoris; Calcium Channel Blockers; Cell Membrane; Diltiazem; Heart; Humans; Hypertension; Muscle Contraction; Muscle, Smooth, Vascular; Myocardial Contraction; Myocardial Infarction; Myocardium; Nifedipine; Perhexiline; Verapamil | 1980 |
Clinical use of calcium entry blockers.
Topics: Angina Pectoris; Calcium Channel Blockers; Cinnarizine; Coronary Circulation; Coronary Vasospasm; Diltiazem; Flunarizine; Heart Rate; Humans; Lidoflazine; Nifedipine; Perhexiline; Verapamil | 1981 |
Effects of perhexiline on hemodynamics in anesthetized open-chest dogs.
Topics: Anesthesia; Animals; Blood Circulation; Blood Flow Velocity; Blood Pressure; Cardiac Output; Dogs; Dose-Response Relationship, Drug; Female; Heart Rate; Hemodynamics; Male; Norepinephrine; Perhexiline; Phentolamine; Piperidines; Propranolol; Verapamil | 1981 |
[Calcium inhibitors. Current indications in cardiology].
Topics: Angina Pectoris; Arrhythmias, Cardiac; Calcium; Cardiovascular Diseases; Diltiazem; Humans; Nifedipine; Perhexiline; Prenylamine; Verapamil | 1980 |